BICX.jpg
BioCorRx Submits Fast Track Application to FDA for BICX104, an Implantable Biodegradable Naltrexone Pellet for The Treatment of Opioid Use Disorder
18 juil. 2023 08h30 HE | BioCorRx Inc
ANAHEIM, CA, July 18, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of innovative treatment programs for substance abuse and...
Excipient Gel Vial
FDA Approves Groundbreaking New Product Utilizing Berkshire Sterile Excipient Gel to Treat 'Butterfly Children'
25 mai 2023 11h10 HE | Berkshire Sterile Manufacturing
Lee, MA, May 25, 2023 (GLOBE NEWSWIRE) -- On May 19, 2023, Krystal Biotech, a client of Berkshire Sterile Manufacturing (BSM), received FDA approval for VYJUVEK™, the first-ever topical gene therapy...
20230503_Updated logo.png
Upon FDA approval, Advanced Medical Balloons launches innovative hygh-tec catheter system for ICU stool drainage in U.S. market
04 mai 2023 08h00 HE | Advanced Medical Balloons GmbH
Creative Balloons operates under new name Advanced Medical Balloons (AMB)AMB’s microscopically thin polyurethane (PUR) balloon catheter systems address indications in intensive care1st product from...
FILSPARI (sparsentan)
Travere Therapeutics Announces FDA Accelerated Approval of FILSPARI™ (sparsentan), the First and Only Non-immunosuppressive Therapy for the Reduction of Proteinuria in IgA Nephropathy
17 févr. 2023 16h04 HE | Travere Therapeutics, Inc.
First single molecule Dual Endothelin Angiotensin Receptor Antagonist (DEARA) approved for use in patients withIgA nephropathy (IgAN)Interim results from the ongoing Phase 3 PROTECT head-to-head trial...
SeaStar_SM_LogoCard.png
SeaStar Medical Receives FDA Approval to Begin Study with Selective Cytopheretic Device to Reduce Hyperinflammation in Adults with Acute Kidney Injury
09 févr. 2023 08h19 HE | SeaStar Medical Holding Corporation
Patient enrollment in pivotal clinical study expected to begin in March DENVER, Feb. 09, 2023 (GLOBE NEWSWIRE) -- SeaStar Medical (Nasdaq: ICU), a medical device company developing proprietary...
FDA Approves Immunotherapy for mNSCLC Patients in Study Conducted at Florida Cancer Specialists & Research Institute
Recent FDA Approval of Advanced Treatment for Patients with Metastatic Non Small-Cell Lung Cancer (NSCLC) Demonstrates Importance of Participation in Clinical Trials
06 déc. 2022 15h41 HE | Florida Cancer Specialists & Research Institute
Ft. Myers, Fla., Dec. 06, 2022 (GLOBE NEWSWIRE) -- A clinical study conducted with participation by Florida Cancer Specialists & Research Institute, LLC (FCS) has led to FDA approval of a new...
WHILL model F and C2 with Stealth Accessories
WHILL Power Chairs Announces Partnership With Stealth Products
24 oct. 2022 12h00 HE | WHILL Inc.
SAN FRANCISCO, Oct. 24, 2022 (GLOBE NEWSWIRE) -- WHILL, Inc., award-winning provider of electric mobility chairs, and Stealth Products LLC, announced a new partnership whereby seating and...
Vial Filling at BSM
Berkshire Sterile client receives FDA approval on product indicated to reduce risk of hearing loss for childhood cancer patients
29 sept. 2022 11h00 HE | Berkshire Sterile Manufacturing
Lee, MA, Sept. 29, 2022 (GLOBE NEWSWIRE) -- On September 21st, 2022, Berkshire Sterile Manufacturing’s (BSM) client, Fennec Pharmaceuticals Inc., received FDA approval of their drug product, PEDMARK...
Arcutis logo.png
FDA Approves Arcutis’ ZORYVE™ (Roflumilast) Cream 0.3% For the Treatment of Plaque Psoriasis in Individuals Age 12 and Older
29 juil. 2022 16h05 HE | Arcutis Biotherapeutics, Inc.
First and only topical PDE4 inhibitor approved for the treatment of plaque psoriasis, including intertriginous psoriasis Approved for once-daily treatment in mild, moderate, and severe plaque...
Neovasc_Logo-web-header.jpg
Neovasc Announces FDA Approval of Planned COSIRA II Sub-studies and Single Arm Registry to Allow Inclusion of Additional Specified Patient Populations
26 juil. 2022 09h05 HE | Neovasc, Inc.
VANCOUVER and MINNEAPOLIS, July 26, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – Neovasc, Inc. ("Neovasc" or the "Company") (NASDAQ, TSX: NVCN) today announced the United States Food and Drug...